Preferred Label : Peroxisome biogenesis disorder 5a (zellweger);
Symbol : PBD5A;
CISMeF acronym : CGF; CG10; CG5; PBD5A;
Type : Phenotype, molecular basis known;
Included titles and symbols : Peroxisome biogenesis disorder, complementation group 5; Peroxisome biogenesis disorder, complementation group 10; Peroxisome biogenesis disorder, complementation group f; CG5; CG10; CGF;
Description : The peroxisomal biogenesis disorder (PBD) Zellweger syndrome (ZS) is an autosomal
recessive multiple congenital anomaly syndrome. Affected children present in the newborn
period with profound hypotonia, seizures, and inability to feed. Characteristic craniofacial
anomalies, eye abnormalities, neuronal migration defects, hepatomegaly, and chondrodysplasia
punctata are present. Children with this condition do not show any significant development
and usually die in the first year of life (summary by Steinberg et al., 2006). For
a complete phenotypic description and a discussion of genetic heterogeneity of Zellweger
syndrome, see 214100. Individuals with PBDs of complementation group 5 (CG5, equivalent
to CG10 and CGF) have mutations in the PEX2 gene. For information on the history of
PBD complementation groups, see 214100.;
Inheritance : Autosomal recessive;
Molecular basis : Caused by mutation in the peroxisome biogenesis factor 2 gene (PEX2, 170993.0001);
Laboratory abnormalities : Absent peroxisomes in skin fibroblasts; Accumulation of very-long-chain fatty acids in serum;
Prefixed ID : #614866;
Origin ID : 614866;
UMLS CUI : C3553940;
Automatic exact mappings (from CISMeF team)
- CG 10 [MeSH Supplementary Concept]
CISMeF manual mappings
Currated CISMeF NLP mapping
DO Cross reference
Genes related to phenotype
HPO term(s)
ORDO concept(s)
Semantic type(s)
UMLS correspondences (same concept)